Genedrive (GB:GDR) has released an update.
Genedrive PLC, a leader in point of care pharmacogenetic testing, announced that its Non-Executive Chairman, Dr. Ian Gilham, has purchased 1,000,000 ordinary shares at 3.1p each on the AIM market of the London Stock Exchange. The company is known for its rapid and effective point of need diagnostic platform, which allows for personalized medicine in emergency healthcare. Genedrive has been recommended by NICE for use in the UK NHS, indicating its growing influence and potential in the healthcare market.
For further insights into GB:GDR stock, check out TipRanks’ Stock Analysis page.
